Variants in the transmembrane 6 superfamily member 2 (TM6SF2) gene are also reported to be associated with disease progression in MASLD, regardless of PNPLA3 polymorphism [8]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.